Core Viewpoint - CervoMed Inc. is set to present findings from the RewinD-LB Phase 2b study of neflamapimod for dementia with Lewy bodies at the upcoming AP/PD™ conference in Vienna, highlighting its focus on age-related neurologic disorders [1][2]. Company Overview - CervoMed is a clinical-stage company dedicated to developing treatments for age-related neurologic disorders, specifically through its investigational drug neflamapimod, which targets synaptic dysfunction associated with neurodegenerative diseases [3]. Presentation Details - The oral presentation will cover the efficacy and safety results of the RewinD-LB Phase 2b clinical trial of neflamapimod in dementia with Lewy bodies, scheduled for April 5, 2025 [2]. - The presentation will be led by John Alam, CEO of CervoMed, and Stephen Gomperts, a prominent neurologist [2].
CervoMed Announces Oral Presentation at 19th International Conference on Alzheimer's and Parkinson's Diseases and Related Neurologic Disorders (AP/PD™)